(Total Views: 187)
Posted On: 03/18/2017 7:36:19 PM
Post# of 15624
Could be, but doesn't really matter when you look at revenue.
BMS is an example where they took the drug Opdivo to other countries and established a market of around $375,000 per year per estimated dosage. Pretty good. Came to the US and it's about $525,000/year.
Point being, US approval is not necessary to have good revenue. And with OWCP I think the majority of revenue will be from outside the US.
Don't know what this means for the stock, but it's JMHO.
BMS is an example where they took the drug Opdivo to other countries and established a market of around $375,000 per year per estimated dosage. Pretty good. Came to the US and it's about $525,000/year.
Point being, US approval is not necessary to have good revenue. And with OWCP I think the majority of revenue will be from outside the US.
Don't know what this means for the stock, but it's JMHO.
(0)
(0)
